A Study of preseasonal treatment with Epinastine Hydrochloride Eyelid Cream 0.5% for Seasonal Allergic Conjunctivitis

A Study of preseasonal treatment with Epinastine Hydrochloride Eyelid Cream 0.5% for Seasonal Allergic Conjunctivitis - A Study of preseasonal treatment with Epinastine Hydrochloride Eyelid Cream 0.5% for Seasonal Allergic Conjunctivitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056448

Enrollment

210

Registered

2024-12-16

Start date

2024-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal Allergic Conjunctivitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects diagnosed with seasonal allergic conjunctivitis in spring before 2024 Subject with seasonal allergic conjunctivitis who visited the eye clinic between the date of signing the contract and February 14, 2025 (before the full-scale dispersal of pollen) requested and were prescribed Epinastine Hydrochloride Eyelid Cream 0.5% or Epinastine Hydrochloride Ophthalmic Solution 0.1% as preseasonal treatment Subjects with seasonal allergic conjunctivitis who visited the eye clinic due to symptoms such as itchy eyes between February 24 and March 24, 2025 requested and were prescribed Epinastine Hydrochloride Eyelid Cream 0.5%

Exclusion criteria

Exclusion criteria: Subjects with severe allergic conjunctival disease (VKC, atopic keratoconjunctivitis) Of the Subjects with seasonal allergic conjunctivitis who visited the eye clinic due to symptoms such as itchy eyes between February 24 and March 24, 2025 requested and were prescribed Epinastine Hydrochloride Eyelid Cream 0.5%, those who used antihistamine eye drops since the end of 2024 up to the time of obtaining consent. Subjects prescribed Epinastine Hydrochloride Eyelid Cream 0.5% who have obvious inflammatory findings on the eyelid skin Subjects with severe allergic conjunctival disease (VKC, atopic keratoconjunctivitis) Of the Subjects with seasonal allergic conjunctivitis who visited the eye clinic due to symptoms such as itchy eyes between February 24 and March 24, 2025 requested and were prescribed Epinastine Hydrochloride Eyelid Cream 0.5%, those who used antihistamine eye drops since the end of 2024 up to the time of obtaining consent. Subjects prescribed Epinastine Hydrochloride Eyelid Cream 0.5% who have obvious inflammatory findings on the eyelid skin Subjects prescribed Epinastine Hydrochloride Eyelid Cream 0.5% with symptoms and findings of atopic dermatitis on the face Subjects prescribed Epinastine Hydrochloride Eyelid Cream 0.5% who are using prescription drugs (steroid eye ointments, steroid ointments, immunosuppressants, etc.) on the eyelid skin Subjects using steroid eye drops or steroid eye ointment

Design outcomes

Primary

Measure	Time frame
Efficacy endpoints Subjective symptoms and QOL score Safety endpoints Adverse events	—

Countries

Japan

Contacts

Public ContactHirotsugu Kishimoto

Santen Pharmaceutical Co., Ltd. Japan Medical Affairs Group

clinical@santen.co.jp03-4802-9337

Outcome results